Reuters logo
BRIEF-Neurocrine Biosciences reports positive results from study of Ingrezza
March 21, 2017 / 1:10 PM / 6 months ago

BRIEF-Neurocrine Biosciences reports positive results from study of Ingrezza

March 21 (Reuters) - Neurocrine Biosciences Inc

* Positive results from Kinect 3 phase iii study of Ingrezza (valbenazine) for treatment of tardive dyskinesia (td)

* Has submitted NDA to FDA for ingrezza and has been granted priority review with a pdufa action date of April 11, 2017

* Says Ingrezza was found to be generally well tolerated with adverse events consistent with those of prior studies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below